Dostarlimab (Jemperli)


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class.
 The inform non-binding recommendations that help guide decisions Canada's federal, provincial, territorial governments, with exception Quebec.
 This review assesses dostarlimab (Jemperli), solution for infusion, 500 mg/10 mL vial (50 mg/mL).
 Indication: Monotherapy treatment adults dMMR MSI-H recurrent advanced endometrial cancer has progressed on after prior platinum-containing regimen.